NCT02724670 Study of MR-based IGRT for Prostate Cancer
| NCT ID | NCT02724670 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Tuebingen |
| Condition | Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 78 participants |
| Start Date | 2016-03 |
| Primary Completion | 2020-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 78 participants in total. It began in 2016-03 with a primary completion date of 2020-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
MR (Magnetic Resonance Imaging) - based IGRT (image-guided radiotherapy) for patients with prostate carcinoma.
Eligibility Criteria
Inclusion Criteria: * histologically proven prostate cancer * indication for curative treatment * ECOG performance scale 0-2 * Informed consent Exclusion Criteria: * contraindications for curative treatment * age\<18year * previous pelvic radiotherapy or prostatic treatment like TURP (transurethral resection of prostate), HIFU (high intensity focused ultrasound) * serious comorbidity leading to inability for IGRT (image-guided radiotherapy) * contraindications for MRI (Magnetic Resonance Imaging)
Contact & Investigator
Arndt-Christian Müller, Dr.
PRINCIPAL INVESTIGATOR
Department of Radiation Oncology, University of Tübingen
Frequently Asked Questions
Who can join the NCT02724670 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02724670 currently recruiting?
Yes, NCT02724670 is actively recruiting participants. Contact the research team at Arndt-Christian.Mueller@med.uni-tuebingen.de for enrollment information.
Where is the NCT02724670 trial being conducted?
This trial is being conducted at Tübingen, Germany.
Who is sponsoring the NCT02724670 clinical trial?
NCT02724670 is sponsored by University Hospital Tuebingen. The principal investigator is Arndt-Christian Müller, Dr. at Department of Radiation Oncology, University of Tübingen. The trial plans to enroll 78 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.